List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. IGF OT IGF RADIOPROTECTOR FOR HEAD AND NECK CANCER PERIOD OF PERFORMANCE

    SBC: BIOMIMETIX JV LLC            Topic: ODNCI

    This SBIR Program is to complete the development of a novel metalloporphyrin antioxidant compound BMX to be used as a radioprotector in the treatment of patients with head and neck cancer undergoing radiation therapy This drug product has been produced to GMP quality safety toxicology completed in one species and a high degree of efficacy demonstrated for both protecting against radiation ...

    SBIR Phase I 2015 Department of Health and Human Services
  2. IGF OT IGF TREATMENT OF TUBERCULOSIS WITH INHALED DELIVERY OF CLOFAZIMINE

    SBC: AEROPHASE INC            Topic: NIAID

    Not Available

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. IGF OT IGF TITLE CHEMO ENZYMATIC SYNTHESIS OF STRUCTURALLY DEFINED COMPLEX TYPE N GLYCANS

    SBC: CHEMILY, LLC            Topic: NCI

    Not Available

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  4. IGF OT IGF SMOKESCREEN GENETIC SCREENING TOOL FOR TOBACCO DEPENDENCE and TREATMENT APPROACHES POP MOD SUPPLEMENT WITHIN SCOPE AND EXTENSION

    SBC: BioRealm LLC            Topic: NIDA

    Not Available

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  5. IGF OT IGF CONTRACT TITLE RADIATION MODULATORS FOR HEAD AND NECK CANCERPOP

    SBC: SuviCa, Inc.            Topic: NCI

    Not Available

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Antibody Secretig Cells ASC in Human Colostridium difficile Infection Colonization and Recurrence

    SBC: MICROBPLEX, INC.            Topic: ODCDC

    The objective of this proposal is the creation of a method for identifying patients with hospital acquired C difficile infections likely to suffer expensive and potentially life threatening recurrences after discharge from the hospital C difficile has emerged as the biggest infectious killer of Americans as well as a multi billion drain on the health care system Most of those costs and mort ...

    SBIR Phase II 2015 Department of Health and Human Services
  7. SERS and Flourescent Dual Mode Dengue Diagnostic Strip Incorporate Novel Nanoparticals

    SBC: Vitan-Biotech LLC            Topic: ODCDC

    Rapid sensitive and specific diagnosis of the Dengue virus DENV infection is important for both patient care and epidemiologic studies Current Dengue diagnostic tests are either time consuming expensive or lack of sensitivity We propose to develop a novel low cost lateralflow immunoassay LFIA strip capable of sensitive detection of DENV NS antigen The proposed test strip synergically in ...

    SBIR Phase I 2015 Department of Health and Human Services
  8. Smartphone Technology for Parents and Teens: Improving Vaccination Uptake

    SBC: KLEIN BUENDEL, INC            Topic: NICHD

    DESCRIPTION provided by applicant Vaccinations for adolescents in the U S tetanus diphtheria and acellular pertussis Tdap meningococcal conjugate vaccine MCV Human Papillomavirus HPV vaccines Gardasil and Cervarex remain well below the Centers for Disease Control and Prevention CDC goals and especially so for the HPV vaccines These vaccine deficits are pronounced among minor ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. High-specificity affinity reagents for the detection of glycan sialylation

    SBC: GLYCOSENSORS AND DIAGNOSTICS, LLC            Topic: 300

    DESCRIPTION provided by applicant Glycans have several distinct properties that make their development as disease biomarkers appealing Firstly their location on cell surfaces makes them the first point of contact for cellular interactions and thus they are crucial in the control of normal metabolic processes and conversely they function as pathogen adhesion receptors Secondly specific gl ...

    STTR Phase I 2015 Department of Health and Human Services
  10. Development of Isotopically Labeled Glycoproteins for use as Internal Standards

    SBC: GlycoScientific, L.L.C.            Topic: 300

    DESCRIPTION provided by applicant The ability to accurately quantitate the glycan chains attached to glycoproteins has wide ranging implications Numerous studies over the past years have demonstrated that abnormal glycosylation occurs in virtually all types of human cancers and demonstrate the potential of using glycan markers in either a diagnostic or a prognostic manner The glycosylatio ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government